Pinealon (Glu-Asp-Arg) is a short tripeptide bioregulator developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the class of 'cytomedins' or 'peptide bioregulators' — short peptides claimed to regulate gene expression and protein synthesis in specific tissues. Pinealon was designed to target the pineal gland and brain. Evidence is limited to Russian-language studies and in vitro work.
Mechanism of Action
According to Khavinson's bioregulator theory, short peptides like Pinealon can interact with DNA promoter regions to regulate gene expression in a tissue-specific manner. In vitro studies suggest Pinealon suppresses free radical production, activates proliferative processes, and may influence signaling molecule expression in pineal cell cultures. These mechanisms are not accepted by mainstream molecular biology and lack independent replication.
Benefits
Increased cell viability by suppressing free radical levels in cell culture[1]
Neuroprotective effects reported in aging models — Russian-language studies[2]
May influence pineal signaling molecule expression in organotypic culture
Part of Khavinson's peptide bioregulator class studied for age-related decline
Not medical advice - research-reported information only
This content is for informational purposes only and does not constitute medical advice.
Pinealon - Dosing in Published Research
Reported routes: Subcutaneous injection, Intranasal, Oral (as part of cytomedin formulations)
No established Western dosing protocols. Khavinson's protocols typically use extremely low doses (micrograms) based on the bioregulator concept. Research chemical dosing is speculative. Some protocols suggest 50–200 μg daily subcutaneously or intranasally, but these are not evidence-based.
The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.
Side Effects
Limited safety data — most studies are in vitro or in aging animal models
The peptide bioregulator concept lacks mainstream scientific acceptance
Long-term effects unknown
Not approved for human use outside Russia
Considering peptide research?
Pinealon is not FDA-approved. Always consult a licensed healthcare provider before considering any peptide.
In vitro study: Pinealon suppressed reactive oxygen species and increased cell proliferation in cultured cells, suggesting antioxidant and cytoprotective properties
Russian-language study reporting neuroprotective effects of peptide bioregulators including Pinealon across age groups
References
1.Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes.. Rejuvenation Res, 2011. "In vitro study: Pinealon suppressed reactive oxygen species and increased cell proliferation in cultured cells, suggesting antioxidant and cytoprotective properties" [PMID: 21978084]
2.Neuroprotective effects of peptides bioregulators in people of various age.. Adv Gerontol, 2013. "Russian-language study reporting neuroprotective effects of peptide bioregulators including Pinealon across age groups" [PMID: 24738258]
Recommended Resources
The Peptide Protocols Handbook
Evidence-based reference guide covering mechanisms, research, and clinical applications.
Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.
Pinealon FAQ
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.